Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siMerTK
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Unknown
01
Overview
siMerTK is an investigational small interfering RNA (siRNA) therapy designed to target the gene encoding MER proto-oncogene tyrosine kinase (MerTK), a receptor tyrosine kinase implicated in regulation of immune responses, cancer progression, and clearance of apoptotic cells. The drug's mechanism of action involves gene silencing via RNA interference, resulting in downregulation of MerTK expression at the post-transcriptional level. The rationale for targeting MerTK includes its role in tissue inflammation, fibrogenesis, and anti-tumor immunity. siMerTK is being evaluated as a research tool and potential therapeutic agent across organ systems, most notably in cardiovascular and metabolic indications[6]. The primary developer appears to be academic or research institutions conducting preclinical or early clinical investigation.
- Brand names
- siMerTK
- Other names
- siMerTK
02
Targets
MERTK (MER proto-oncogene, tyrosine kinase)
Beyond the preview
Go deeper on siMerTK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siMerTK.